Loading
Life sciences · Journal article
BMC Pulmonary Medicine · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ObjectiveTo evaluate whether upfront brain radiotherapy confers a survival benefit in patients with asymptomatic brain metastases from non-small cell lung cancer (NSCLC) receiving first-line third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).MethodsWe retrospectively analyzed 163 pathologically confirmed NSCLC patients with asymptomatic brain metastases who received third-generation EGFR-TKIs as first-line therapy. Patients were stratified according to whether they received early brain radiotherapy in addition to EGFR-TKI treatment. Survival outcomes were compared between groups.ResultsAmong the 163 patients, 81 received combined EGFR-TKI therapy and brain radiotherapy, while 82 received EGFR-TKI monotherapy. The overall response rate (ORR) was significantly higher in the combination group than in the monotherapy group (95.1% vs. 80.1%, P = 0.001). Median iPFS, PFS, and OS were also significantly prolonged in the combination group compared with EGFR-TKI alone (18.4 vs. 12.8 months, P = 0.003; 17.6 vs. 12.8 months, P = 0.004; and 37.1 vs. 25.8 months, P = 0.010, respectively). Subgroup analyses demonstrated that in patients with oligometastatic brain disease, combined therapy significantly improved iPFS (26.4 vs. 16.5 months, P = 0.011), PFS (26.2 vs. 16.5 months, P = 0.010), and OS (42.4 vs. 29.7 months, P = 0.007) compared with EGFR-TKI monotherapy. In contrast, among patients with multiple brain metastases, no significant differences in iPFS, PFS, or OS were observed between treatment groups. Conclusion: Early brain radiotherapy is associated with improved survival outcomes in patients with asymptomatic brain metastases from NSCLC treated with third-generation EGFR-TKIs, particularly in those with oligometastatic disease.